{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:01:45Z","timestamp":1780837305218,"version":"3.54.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To identify genetic variants that influence steady-state etonogestrel concentrations among contraceptive implant users.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We enrolled healthy, reproductive-age women in our pharmacogenomic study using etonogestrel implants for 12\u201336 months without concomitant use of hepatic enzyme inducers or inhibitors. We collected participant characteristics, measured serum etonogestrel concentrations, and genotyped each participant for 120 single nucleotide variants in 14 genes encoding proteins involved in steroid hormone (ie, estrogens, progestins) metabolism, regulation, or function. We performed generalized linear modeling to identify genetic variants associated with steady-state etonogestrel concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>We enrolled 350 women, who had a median serum etonogestrel concentration of 137.4 pg\/mL (range 55.8\u2013695.1). Our final generalized linear model contained three genetic variants associated with serum etonogestrel concentrations: <jats:italic toggle=\"yes\">NR1I2(PXR)<\/jats:italic> rs2461817 (\u03b2=13.36, <jats:italic toggle=\"yes\">P<\/jats:italic>=.005), PGR rs537681 (\u03b2=\u221229.77, <jats:italic toggle=\"yes\">P<\/jats:italic>=.007), and <jats:italic toggle=\"yes\">CYP3A7*1C<\/jats:italic> (\u03b2=\u221235.06, <jats:italic toggle=\"yes\">P<\/jats:italic>=.025). Variant allele frequencies were 69.4%, 84.9%, and 5.1%, respectively. Our linear model also contained two nongenetic factors associated with etonogestrel concentrations: body mass index (BMI) (\u03b2=\u22123.08, <jats:italic toggle=\"yes\">P<\/jats:italic>=7.0\u00d710<jats:sup>\u22127<\/jats:sup>) and duration of implant use (\u03b2=\u22121.60, <jats:italic toggle=\"yes\">P<\/jats:italic>=5.8\u00d710<jats:sup>\u22125<\/jats:sup>); R<jats:sup>2<\/jats:sup> for the model =0.17.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Only BMI and duration of implant use remained significantly associated with steady-state etonogestrel concentrations. Of the three novel genetic associations found, one variant associated with increased etonogestrel metabolism (<jats:italic toggle=\"yes\">CYP3A7*1C<\/jats:italic>) causes adult expression of fetal CYP3A7 proteins and can consequently alter steroid hormone metabolism. Women with this variant may potentially have increased metabolism of all steroid hormones, as 27.8% (5\/18) of <jats:italic toggle=\"yes\">CYP3A7*1C<\/jats:italic> carriers had serum etonogestrel concentrations that fell below the threshold for consistent ovulatory suppression (less than 90 pg\/mL). More pharmacogenomic investigations are needed to advance our understanding of how genetic variation can influence the effectiveness and safety of hormonal contraception, and lay the groundwork for personalized medicine approaches in women's health.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT03092037.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003189","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:58:14Z","timestamp":1553615894000},"page":"783-794","source":"Crossref","is-referenced-by-count":37,"title":["Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users"],"prefix":"10.1097","volume":"133","author":[{"given":"Aaron","family":"Lazorwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Aquilante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Oreschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanelle","family":"Sheeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Guiahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Teal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/ctr.12790","article-title":"CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients","volume":"30","author":"Deininger","year":"2016","journal-title":"Clin Transplant"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2133\/dmpk.DMPK-13-RG-077","article-title":"Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults","volume":"29","author":"Sukasem","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr Drug Metab"},{"key":"R7-20230711","first-page":"1","article-title":"Current contraceptive status among women aged 15\u201344: United States, 2011\u20132013","author":"Daniels","year":"2014","journal-title":"NCHS Data Brief"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0022-4731(83)90017-1","article-title":"Variability of pharmacokinetic parameters for contraceptive steroids","volume":"19","author":"Fotherby","year":"1983","journal-title":"J Steroid Biochem"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"586.e1","DOI":"10.1016\/j.ajog.2017.01.036","article-title":"Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration","volume":"216","author":"McNicholas","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.AOG.0000263922.08190.3b","article-title":"Brand versus generic oral contraceptives. ACOG Committee Opinion No. 375. American College of Obstetricians and Gynecologists","volume":"110","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.qai.0000225013.53568.69","article-title":"Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study","volume":"42","author":"Anderson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/FPC.0b013e3283636856","article-title":"A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients","volume":"23","author":"Tavira","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R16-20230711","first-page":"1","article-title":"Contraceptive methods women have ever used: United States, 1982\u20132010","author":"Daniels","year":"2013","journal-title":"Natl Health Stat Rep"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1345\/aph.10149","article-title":"Implanon: a critical review","volume":"35","author":"Le","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R18-20230711","first-page":"303","article-title":"The effects of extremes of age on drug action","volume":"2","author":"Wilson","year":"1980","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.contraception.2015.11.005","article-title":"Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year","volume":"93","author":"Morrell","year":"2016","journal-title":"Contraception"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/FTD.0b013e31829a10fa","article-title":"A UPLC-MS\/MS method for therapeutic drug monitoring of etonogestrel","volume":"35","author":"Thomas","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R24-20230711","first-page":"105","article-title":"Log-transformation and its implications for data analysis","volume":"26","author":"Feng","year":"2014","journal-title":"Shanghai Arch Psychiatry"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference: understanding AIC and BIC in model selection","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociological Methods Res"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000091787","article-title":"Quantification of the power of Hardy-Weinberg equilibrium testing to detect genotyping error","volume":"61","author":"Cox","year":"2006","journal-title":"Hum Hered"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"e1007394","DOI":"10.1371\/journal.pgen.1007394","article-title":"Whole exome sequencing reveals HSPA1L as a genetic risk factor for spontaneous preterm birth","volume":"14","author":"Huusko","year":"2018","journal-title":"PLoS Genet"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","volume":"46","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.fpc.0000171516.84139.89","article-title":"CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele","volume":"15","author":"Sim","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/0008-5472.CAN-15-1410","article-title":"Cytochrome P450 allele CYP3A7*1C associates with adverse outcomes in chronic lymphocytic leukemia, breast, and lung cancer","volume":"76","author":"Johnson","year":"2016","journal-title":"Cancer Res"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2016.432","article-title":"CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites","volume":"116","author":"Sood","year":"2017","journal-title":"Br J Cancer"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-011-1171-8","article-title":"Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics","volume":"68","author":"Brennan","year":"2012","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201904000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:49:02Z","timestamp":1689104942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201904000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003189","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}